Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study

Zinger Key Points
  • The progression-free survival (PFS) benefit was demonstrated across clinical subgroups.

On Friday, Summit Therapeutics Inc SMMT shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday.

Thursday, Summit Therapeutics Inc SMMT announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS).

HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%).

The HARMONi-2 is a single-region, multi-center, double-blinded Phase 3 study conducted in China sponsored by Akeso Inc. with data generated and analyzed by Akeso.

At a prespecified interim analysis conducted by an independent Data Monitoring Committee, ivonescimab demonstrated a statistically significant and clinically meaningful improvement in PFS by the blinded independent central radiology review committee (BICR) compared to Merck & Co Inc’s MRK Keytruda (pembrolizumab).

The progression-free survival (PFS) benefit was demonstrated across clinical subgroups, including those with PD-L1 low expression, PD-L1 high expression, squamous and non-squamous histologies, and other high-risk patients.

There are no known Phase 3 clinical trials in NSCLC that have shown a statistically significant improvement compared to pembrolizumab in a head-to-head setting.

Price Action: SMMT shares are down 28.60% at $7.80 at last check on Friday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareTop StoriesMoversMediaTrading IdeasGeneralBriefsStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!